IQUIBICEN   23947
INSTITUTO DE QUIMICA BIOLOGICA DE LA FACULTAD DE CIENCIAS EXACTAS Y NATURALES
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
In vitro antiviral activity of λ carrageenan against DENV infection of human myeloid cells in absence or presence of antibodies
Autor/es:
PICCINI, L.E.; CARRO, A.C.; DAMONTE, E.B.
Reunión:
Conferencia; 31st International Conference on Antiviral Research; 2018
Resumen:
Dengue is the most prevalent arthropod-borne viral human disease in tropical and subtropical regions, caused by four dengue virus (DENV) serotypes. In spite of the increasing global incidence, no specific antiviral therapy is available. Cells of the mononuclear phagocyte lineage are the main targets either for primary or secondary antibody (Ab)-mediated DENV infection, usually associated to severe forms of disease. Since virus entry may be a convenient therapeutic alternative, this study aimed to investigate the antiviral activity of λ carrageenan against DENV infection, in the presence and absence of Ab, in monocytic U937 cells and erythroleukemic K562 cells. The carrageenan was non cytotoxic for both human cells as determined by trypan blue exclusion method at concentrations up to 1 mg/ml. The antiviral effective concentration 50 % (EC50), measured by virus yield inhibition, was lower than 1.25 µg/ml against primary infection of both myeloid cells with all DENV serotypes. In Ab-mediated infection, the inhibitory activity was dependent on the cell and the Ab. In K562 cells, where immune complex entry is mediated through FcRII, the carrageenan was always inhibitory of Ab-mediated infection whereas in U937 cells, that express both FcRI and FcRII, there was inhibition only when FcRII was involved in Ab-dependent entry. The early events of virus adsorption and internalization were the targets of carrageenan in primary and Ab-mediated infection of myeloid cells. These results confirm that diverse factors of virus-host interaction should be considered for evaluation of safe entry inhibitors reactive against primary and secondary DENV infections.